Gitelson, E., Al-Saleem, T., Millenson, M., Lessin, S., Smith, M.R. Cutaneous B cell lymphoma responds to rituximab: Report of 5 cases and review of the literature. Leukemia Lymphoma 47:1902-1907, 2006.
Hoppe, R.T., Advani, R.H., Bierman, P.J., Bloomfield, C.D., Buadi, F., Djulgegovic, B., Forero, A., Gordon, L.I., Hernandez-Ilizaliturri, F.J., Kaminski, M.S., Love, G., Maloney, D.G., Mauch, P.M., Moore, J.O., Schilder, R.J., Weiss, L., Winter, J.N., Yahalom, J., Zelenetz, A.D. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 4:210-230, 2006.
Narra, K., Borghaei, H., Al-Saleem, T., Hoglund, M, Smith, M.R. Pure red cell aplasia in B-cell lymphoproliferative disorders successfully treated with rituximab: Report of two cases and review of literature. Leuk. Res. 30:109-114, 2006.
O'Donnell, M.R., Appelbaum, F.R., Baer, M.R., Byrd, J.C., Coutre, S.E., Damon, L.E., Erba, H.P., Estey, E., Foran, J., Lancet, J., Maness, L.J., Maslak, P.G., Millenson, M., Moore, J.O., Przepiorka, D., Shami, P., Smith, B.D., Stone, R.M., Tallman, M.S. Acute myeloid leukemia clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 4:16-36, 2006.
Redfern, C.H., Guthrie, T.H., Bessudo, A., Densmore, J.J., Holman, P.R., Janakiriman, N., Leonard, J.P., Levy, R.L., Just, R.G., Smith, M.R., Rosenfelt, F.P., Wiernik, P.H., Carter, W.D., Gold, D.P., Melink, T.J., Gutheil, J.C., Bender, J.F. Idiotype Vaccination Induces Durable Clinical Responses in Previously Treated Patients with Indolent Non-Hodgkin’s Lymphoma: A Phase II Trial. J. Clin. Oncol. 24:3107-3112, 2006.
Roberts, J.D., Smith, M.R., Feldman, E.J., Cragg, L. Honeycutt, C., Carter, W.H., Millenson, M.M., Padavic, K., Ramakrishnan, V., Murgo, A.J., Grant, S. Phase 1 study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin’s) lymphoma. Clin Cancer Res 12:5809-5816, 2006.
Smith, M.R., Joshi, I., Jin, F., Al-Saleem, T. Murine Model for Mantle Cell Lymphoma. Leukemia 20:891-893, 2006.
Zelenetz, A.D., Advani, R.H., Buadi, F., Cabanillas, F., Caliguri, M.A., Czuczman, M.S., Damon, L.E., Fayad, L., Flinn, I.W., Forero, A., Glenn, M.J., Gockerman, J.P., Gordon, L.I., Harris, N.L., Hoppe, R.T., Kaminski, M.S., LaCasce, A.S., Nademanee, A., Porcu, P., Press, O., Prosnitz, L., Smith, M.R., Sotomayor, E.M., Vose, J.M., Yahalom, J. Non-Hodgkin’s lymphoma: Clinical practice guidelines in oncology. J NCCN 4:258-310, 2006.
Smith, M.R., Joshi, I., Jin, F., Obasaju, C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against non-Hodgkins lymphoma cell lines in vitro and in scid mice. Biomed. Central Cancer 5:103-106, 2005.
Smith, M.R, Borghaei, H. Comment on "Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study," by Kahl, et al. Cancer Invest. 23:572, 2005.
Arias-Mendoza, F., Smith, M.R., Brown. T.R. Predicting treatment response in non-Hodgkins lymphoma by phosphorous magnetic resonance spectroscopy. Acad. Radiol. 11:366-378, 2004.
Borghaei, H., Schilder, R., Millenson, M., Alden, M., Rogatko, A., Wang, H., Padavic-Shaller, K., Smith, M.R. Phase II study of paclitaxel and estramustine In relapsed and refractory non-Hodgkins lymphoma. Cancer 101(9):2034-2041, 2004.
Ibrahim, D., Smith, M.R., Varterasian M., Karanes, C., Millenson, M.,Yeslow, G., Pemberton, P., Lai, P., Abrams, J., Al-Katib, A. Phase II study of PEND chemotherapy in relapsed/refractory Hodgkin lymphoma. Leuk. Lymphoma 45:2079-2084, 2004.
Morris, G.J., Millenson, M.M., Padavic-Shaller, K., Wang, H., Rogatko, A., Clyde, J., Boyd, R.L., Yeslow, G., Halbherr, T., Schilder, R.J., Smith, M.R. Phase II study of fludarabine and α-interferon in patients with low-grade non-Hodgkins lymphoma. Haematologica 89(12):1484-1491, 2004.
Smith, M.R., Jin, F., Joshi, I. Enhanced efficacy of therapy with antisense bcl-2 oligonucleotides + anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Mol. Cancer Ther. 3(12):1693-1699, 2004.
Smith, M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359-7368, 2003.
Wiseman, G.A., Leigh, B.R., Erwin, W.D., Sparks, R.B., Podoloff, D.A., Schilder, R.J., Bartlett, N.L., Grillo-Lopez, A.J., Witzig, T.E., White, C.A. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother. Radiopharm. 18:165-178, 2003.
Wu, H., Smith, M.R., Millenson, M.M., Nicolaou, N., Van Deerlin, M., Addya K., Lessin, S., Al-Saleem, T. Contribution of flow cytometry in the diagnosis of cutaneous lymphoid lesions. J. Invest. Dermatol. 121(6):1522-1530, 2003.
Franks, S.E., Smith, M.R., Arias-mendoza, F., Shaller, C., Padavic-Shaller, K., Kappler, F., Zhang, Y., Negendank, W.G., Brown, T.R. Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk. Res. 26(10):919-926, 2002.
McGinness, K.S., Shapiro, M., Junkins-Hopkins, J.M., Smith, M.R., Lessin, S.R., Vittorio, C.C., Rook, A.H. Denileukin diftitox (Ontak?) for the treatment of panniculitic lymphoma. Arch. Dermatol. 138:740-742, 2002.
Roberts, J., Smith, M., Feldman, E., Grant, S. Phase I trial of bryostatin 1 (NSC 399555) and fludarabine in patients with progressive CLL and indolent non-Hodgkin's lymphoma. Clin. Lymphoma 3:184-188, 2002.
Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S. Bartlett, N.J. Schilder, R.J., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336-42, 2002.
Schilder, R.J., Gallo, J., Millenson, M.M., et al. Phase I trial of multiple cycles of high dose carboplatin, paclitaxel and topotecan with peripheral blood stem cell support as front-line therapy. J. Clin. Oncol. 19(4):1183-1194, 2001.
Smith, M.R., Xie, T., Zhou, Z.-Z., Joshi, I. Efficacy of treatment with antisense oligonucleotides complementary to immunoglobulin sequences of bcl-2/immunoglobulin fusion transcript in a t(14;18) human lymphoma-scid mouse model. Clin.Cancer Res. 7:400-406, 2001.
The information in the below link is obtained from Pubmed.
Publications by Mitchell Smith on Pubmed.
